Duloxetine-related posterior reversible encephalopathy syndrome: A case report

BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) has well-established links with several drugs. Whether a link also exists with serotonin–norepinephrine reuptake inhibitor such as duloxetine is unclear. METHODS: We report on a patient who developed PRES with a coma and myoclonus relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zappella, Nathalie, Perier, François, Pico, Fernando, Palette, Catherine, Muret, Alexandre, Merceron, Sybille, Girbovan, Andrei, Marquion, Fabien, Legriel, Stephane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2016
Materias:
5300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370806/
https://www.ncbi.nlm.nih.gov/pubmed/27537580
http://dx.doi.org/10.1097/MD.0000000000004556
_version_ 1782518300870180864
author Zappella, Nathalie
Perier, François
Pico, Fernando
Palette, Catherine
Muret, Alexandre
Merceron, Sybille
Girbovan, Andrei
Marquion, Fabien
Legriel, Stephane
author_facet Zappella, Nathalie
Perier, François
Pico, Fernando
Palette, Catherine
Muret, Alexandre
Merceron, Sybille
Girbovan, Andrei
Marquion, Fabien
Legriel, Stephane
author_sort Zappella, Nathalie
collection PubMed
description BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) has well-established links with several drugs. Whether a link also exists with serotonin–norepinephrine reuptake inhibitor such as duloxetine is unclear. METHODS: We report on a patient who developed PRES with a coma and myoclonus related to hypertensive encephalopathy a few days after starting duloxetine treatment. Magnetic resonance imaging was performed and catecholamine metabolites assayed. RESULTS: The patient achieved a full recovery after aggressive antihypertensive therapy and intravenous anticonvulsant therapy. CONCLUSIONS: The clinical history, blood and urinary catecholamine and serotonin levels, and response to treatment strongly suggest that PRES was induced by duloxetine. Duloxetine should be added to the list of causes of PRES.
format Online
Article
Text
id pubmed-5370806
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-53708062017-03-31 Duloxetine-related posterior reversible encephalopathy syndrome: A case report Zappella, Nathalie Perier, François Pico, Fernando Palette, Catherine Muret, Alexandre Merceron, Sybille Girbovan, Andrei Marquion, Fabien Legriel, Stephane Medicine (Baltimore) 5300 BACKGROUND: Posterior reversible encephalopathy syndrome (PRES) has well-established links with several drugs. Whether a link also exists with serotonin–norepinephrine reuptake inhibitor such as duloxetine is unclear. METHODS: We report on a patient who developed PRES with a coma and myoclonus related to hypertensive encephalopathy a few days after starting duloxetine treatment. Magnetic resonance imaging was performed and catecholamine metabolites assayed. RESULTS: The patient achieved a full recovery after aggressive antihypertensive therapy and intravenous anticonvulsant therapy. CONCLUSIONS: The clinical history, blood and urinary catecholamine and serotonin levels, and response to treatment strongly suggest that PRES was induced by duloxetine. Duloxetine should be added to the list of causes of PRES. Wolters Kluwer Health 2016-08-19 /pmc/articles/PMC5370806/ /pubmed/27537580 http://dx.doi.org/10.1097/MD.0000000000004556 Text en Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle 5300
Zappella, Nathalie
Perier, François
Pico, Fernando
Palette, Catherine
Muret, Alexandre
Merceron, Sybille
Girbovan, Andrei
Marquion, Fabien
Legriel, Stephane
Duloxetine-related posterior reversible encephalopathy syndrome: A case report
title Duloxetine-related posterior reversible encephalopathy syndrome: A case report
title_full Duloxetine-related posterior reversible encephalopathy syndrome: A case report
title_fullStr Duloxetine-related posterior reversible encephalopathy syndrome: A case report
title_full_unstemmed Duloxetine-related posterior reversible encephalopathy syndrome: A case report
title_short Duloxetine-related posterior reversible encephalopathy syndrome: A case report
title_sort duloxetine-related posterior reversible encephalopathy syndrome: a case report
topic 5300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370806/
https://www.ncbi.nlm.nih.gov/pubmed/27537580
http://dx.doi.org/10.1097/MD.0000000000004556
work_keys_str_mv AT zappellanathalie duloxetinerelatedposteriorreversibleencephalopathysyndromeacasereport
AT perierfrancois duloxetinerelatedposteriorreversibleencephalopathysyndromeacasereport
AT picofernando duloxetinerelatedposteriorreversibleencephalopathysyndromeacasereport
AT palettecatherine duloxetinerelatedposteriorreversibleencephalopathysyndromeacasereport
AT muretalexandre duloxetinerelatedposteriorreversibleencephalopathysyndromeacasereport
AT merceronsybille duloxetinerelatedposteriorreversibleencephalopathysyndromeacasereport
AT girbovanandrei duloxetinerelatedposteriorreversibleencephalopathysyndromeacasereport
AT marquionfabien duloxetinerelatedposteriorreversibleencephalopathysyndromeacasereport
AT legrielstephane duloxetinerelatedposteriorreversibleencephalopathysyndromeacasereport

Ejemplares similares